Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reading through this Press Release, there are some points that are interesting for future timing of the IND. Looks like they have done or are completing animal studies (Note the "veterinary ophthalmologist" and "followed with histological analysis". Histology lab work appear to be the next step--but that usually does not take long.
Saw the Pipeline Page that was under construction for far too long. Better late than never. But all this activity behind the scenes that is going into the public domain now has to be for a reason for partnership possibilities, future up listing, etc.
JMO, but this trading on a pre-holiday day maybe wans not the best timing, but maybe there is a reason for \doing it if they have more pending news. Playing catch up with the Presentation and Pipeline page on the website followed with thhis development update in the PR.
CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
Company’s First In-license Pipeline Product to Enter Pre-clinical Studies
Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today the company has advanced into ocular tolerance evaluation of various metformin eye drop formulations.
As a significant step towards moving into human clinical trials, the current studies focus on tolerability and pharmacokinetics which will assess the ocular tissue distribution after topical ocular delivery of metformin. These studies will aid in optimization of the formulation and build evidence to ensure adequate exposure and safety via topical ocular delivery, which will support the company to move into Good Laboratory Practice (GLP) toxicology studies for an IND filing.
Ocular tolerance includes observations at dosing, general clinical observations twice daily (evaluation of behavior/clinical signs with particular attention paid to the eyes), ophthalmic examinations by a board-certified veterinary ophthalmologist according to the modified Hackett-McDonald scoring scale, and ocular histopathology.
Paul Michaels, Chairman and President of Curative Biotech said, “Significantly for our future IND filing, we are also measuring metformin concentration in the plasma to evaluate systemic exposure. We are conducting studies which will be followed with histological analysis.”
Future Curative Biotechnology Press Releases and Industry Updates
Interested investors and shareholders will receive press releases and industry updates by sending an e-mail to ir@curativebiotech.com.
About Curative Biotechnology, Inc. http://curativebiotech.com
Curative Biotech is a development-stage biomedical company focusing on novel treatments for rare or currently unmet medical needs. Curative Biotech is focused on therapies with potentially accelerated development paths resulting from either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease.) At Curative Biotech, we envision a world where all patients have a therapeutic option.
Interesting news. Looks like next step is that IND. And reformulations is encouraging. They are farther along than I expected
Sticktwits is ge5ting more active on CUBT too.
Learned a long time ago to take profits when they are given so fast
The first drug it talks about is Metformin eye drops. Which should be IND in a couple of months.
Vaccine deal was in a few slides.
BB--CUBT apparently added a Powerpoint Presentation to their websit thsi afternoon.
https://curativebiotech.com/news-and-media/presentations
Any thought on what you see here?
TIA
3F--you have been around the block a few times.
Check out this Powerpoint. https://curativebiotech.com/news-and-media/presentations
I would value your thoughts given your experience.
Thank in advanc
CUBT Powerpoint Presentation on their website
https://curativebiotech.com/news-and-media/presentations
Some really good information. Finally.
Explains the business plan pretty good. And talks about Intellectual Property. I always like a good IP portfolio.
Just good to see that they are starting to communicate again.
Ford tough
Anyone notice a presentation on the website? It wasn't there on Friday
Checked their last filing where any financing would have been disclosed Cannot find ANY toxic financing. Capital was raised at higher prices for cash for restricted stock.
Frankly, for a micro cap, this company is pretty "clean" in that everything that has been done so far has been done frugally. No huge dilution.
If any one can provide me with a link and an actual disclosure of toxic financing, please post.
It is counterproductive to talk about toxic financing when there has been none.
Trying to help here with facts and not unfounded assumptions or accusations.
Not as bad a reaction to the RS as I thought. Moving to a higher exchange is a long term positive. Easier to obtain capital and getting some institutional interest too.
It would help if they would not be at this price once the RS is done. Wise move would be releasing some positive news if they have it.
First clinical trial coming up
https://www.medicaldialogues.in/ophthalmology/news/low-dose-of-metformin-may-prevent-development-of-amd-jama-study-74000
Would not be surprised to see them up list BEFORE the IND filing for Metformin treatment for Macular Degeneration. There probably is a quicker route --shorter safety studies--because the drug has been used for decades for the treatment of diabetes.
Probably safety studies for the eye drop application. And them eye patients.\
But if they filed to get on NASDAQ and --AND --filed the IND, that would be sweet.
Weak hands that get scared out of a good company can really set you up for a major trade.
Know what I mean?
I think that this Notice was a requirement in the State of Florida and has no bearing on the actual possibility.
I tried to call the FL Sec. of State's office regarding this to make sure, but the hold time was longer than calling my cable company.
"The stock tends to rally beforehand. Different reasons cause this such as short covering but the MMs almost always bring it up beforehand."
I have seen it often. Especially when MM's who can see the book of orders, can and do short for their own account. Bet UNQL has good news to run the stock to prompt short covering before the rs.
Like you said, not all RS's are bad. And if you have cajones to average in at lower prices a he weak hands sell, you get cheap stock before the potential run up.
Agreed about that ridiculous 10,000 number, EAGLE. There is no conceivable way that they would need to do a 1 for 10,000. Either that is a boiler plate notice to cover their bases or a lazy attorney that could have easily change the number to much lower one.
IMHO, the only reason they put out that notice is for a filing to NASDAQ or NYSE SM. They have plenty of room at the current prices to raise capital (current shares outstanding vs. authorized), so the only reason, imo, is for the company to get the required higher stock price to get to a higher exchange. If they are smart, they will only move to do that with real capital coming in requiring an uplisting AND not at the current prices.
They would be stupid to do a rs at these prices--and it will require some news or development to change this trend. But buying in down here, imo short term opinion, will look smart by January when tax loss selling is over and the company has updated shareholders including the timing of the delayed IND filing.
I would not mind getting on NASDAQ with a partner and/or capital. Just would like to see a modest 1 for 10 split or even better to get there.
FWIW
UNQL chart
Agreed. Sometimes a RS, if used to move to a higher exchange, is the most advisable way to attract capital and build a business. Getting on NASDAQ changes the investor base (yes, away from penny stock players) but also brings in institutions, research and...more stability.
The bad RS's are the ones where there is no progress in the business plan, the shares outstanding is bumping up against the authorized limit, and more dilution is clearly necessary.
Not the case here.
So TSLA gets a huge valuation because they do ONLY EV-pure play. Ford is diversified and getting into EV in a big way, but the jury is still out in the eyes of the market on what their sales will be. SO, F is at a market valuation discount to Tesla (so is every other legacy auto company, BTW).
But when some preliminary EV numbers show a nice ramp up of consumer adoption, and Ford's total production starts shifting significantly to EV, Ford will not be at these prices.
Jmo
Seems like he has bought some convertible debt and direct investment in some other small companies in the past. Small, struggling companies. You can sometimes make some coin by buying discounted stock by funding a company directly. Did not see any company where he was an insider per se --just a direct investor requiring his name to show up in filings.
Looks like most of those tickers were from over 10 years ago during the Great Recession.
Cannot find anything where he was listed as any kind of officer until CTYX/CUBT. But the way he became involved in CUBT as a big investor was apparently by buying out the preferreds from CTYX management when it was basically a non-operating shell.
Great price to buy out CTYX management. Now he cannot take advantage of the price move now--or when it was a .22. He is stuck with us until the company becomes fully reporting. LOL. Either he succeeds in building this company and becoming SEC reporting or he spent a lot of time getting people on board and getting patents for nothing. Obviously, my "bet" is that there is more to this story with Metformin, rabies, brain cancer etc. than just wasting time.
Wish I can say that I bought in low for the first time. Three Flight got me interested in the lower teens. Betting that buying when there is "blood in the streets" turns out to be wise.
GLTA
Lots of flipping going on on Friday.
GTC order to buy @ $0.065 just hit my acct. Surprised, but averaging down is the wise move, imo
That said, my buying is based on an expectation that the Company will have more communication with Shareholders soon ie. CEO blog, website update on pipeline, news on IND in first quarter and some update on reformulation of Metformin eye drops.
Tax loss selling is a factor here too.
GLTA
THREE clinical programs. Sounds to me that there should be, at least, one of those programs close to starting. Why else has she been retained?
Does a rising tide lift all EV boats?
F wants to be known as a technology company like TSLA. And minimize supply chain issues with their own chips.
Wonder what would happen if they pulled the talk of an RS?
Either they are close to something that would require an uplisting and a RS to do that.
Or they have to file the notice to have flexibility to do an uplisting at some point.
Maybe they are bringing in more capital that needs a Nasdaq listing so they can fund multiple trials at the same time.
F150 EV that can be plug into your home if you lose power is a great feature.
Good point. If they really wanted to hurt Shareholders, they would have waited to convert until after a RS.
Agreed-- the reformulation for eye drop delivery of metformin would be a big step towards attracting attention from potential partners.
With the long safety history of metformin in pill form, the key would be arriving at a safe formulation to the eye at a dosage that is also effective.
Safety studies usually start with animal studies--and that can be a short process here. Followed by human trials that should be a easy recruitment process.
RIDE has been a rough ride this year. But EV tax credits should help the entire sector.
F can use the capital from selling their Rivian stake to build out their EV production.
What does Frank get in Income? You probably know off the top of your head.
Agreed, iRobot. The sooner the company provides more info on the pipeline, milestones, whatever, the better for the shareholders and the stock price.
No one wants to get into a biotech that has no new News out.
Now, for a little smile for the future:
DOES METFORMIN AFFECT EYESIGHT?
Oct 4, 2021
The Connection Between Diabetes and Vision
Does Metformin Affect Eyesight?
Metformin is a medication that is commonly used in the treatment of diabetes. Researchers have found that metformin can protect the eyes from age-related macular degeneration, which is very common in older patients who have diabetes.
Some ophthalmologists estimate that a metformin prescription can give elderly patients another 10 years of functioning eyesight.
Metformin & Diabetes Treatment
It requires a multipronged approach to protect eyesight from the damage diabetes can cause, and metformin is often part of this treatment approach.
Metformin is a medication that is either used by itself or with other medications to treat type 2 diabetes (when the body does not use insulin typically and cannot manage the sugar levels in the blood). Metformin helps the body do this, by decreasing the amount of glucose (sugar) that is absorbed from food and the amount of glucose that is produced by the liver. Metformin also increases the body’s response to insulin, which the body would normally produce to control glucose levels in the blood.
Left untreated, diabetes and high blood sugar levels can lead to heart disease, kidney problems, nerve damage, stroke, and eye and vision issues. Patients with diabetes might have a higher risk of blindness because the excessive blood sugar levels in their blood might damage their eyes and their optic nerve.
Metformin can be very helpful in addressing these issues, but patients will also be encouraged to make lifestyle changes (like improving their diet and getting regular exercise) and frequently check their blood sugar levels to control their diabetes and their sugar levels.
How Metformin Protects Eyesight
Metformin is considered the “medication of choice” as the first option to treat type 2 diabetes. This is because it provides many other health benefits in addition to lowering blood sugar.
Metformin can reduce the risk of high blood pressure affecting vision, and some researchers have discovered that the medication can also reduce the development of age-related macular degeneration (AMD), which is the leading cause of vision loss among people over the age of 50. People who have diabetes are at a high risk for developing AMD.
The researchers, based in Taiwan, told the Annual Meeting of the American Academy of Ophthalmology in 2018 that patients on a prescription of metformin had a 50 percent lower risk of getting age-related macular degeneration compared with patients who were not taking the medication.
Protective Against Inflammation
This led the researchers to conclude that metformin had a “protective effect” on the eyes, shielding eyesight from the effects of AMD, such as:
Partial loss of vision.
Straight lines appearing wavy.
Blurry vision.
Seeing spots in the field of view.
Inability to see in low-light conditions.
The researchers theorized that because metformin has both anti-inflammation and antioxidation properties, it might reduce the occurrence of age-related macular degeneration. This is because inflammation and oxidative stress are part of the development of diabetes and AMD.
Metformin has also been connected to improving eyesight in patients who have diabetic retinopathy. Researchers writing in the American Journal of Translational Research in 2017 investigated the underlying mechanisms of how metformin both delayed the development and reduced the severity of diabetic retinopathy. They concluded that metformin has a “previously unappreciated role [...] in the prevention of development of diabetic retinopathy.”
10 Years of Vision
Some researchers have found that metformin stimulates metabolism in the retinal cells of the eye, creating energy production that makes the cells stronger against the development of age-related macular degeneration. An ophthalmology researcher at the University of Florida College of Medicine explained that metformin “allows these cells in the retina to be harder and more resistant to damage.”
Metformin is an inexpensive, widely used medication without many documented side effects, so doctors are hopeful that more patients with diabetes will use it to stave off vision loss.
Metformin makes cells gather together and use glucose as an energy source. Keeping them at this level of functionality can reduce damage to DNA and the effects of oxygen being metabolized by high blood sugar levels. By activating a protective enzyme, metformin can protect eyesight from the effects of diabetes.
Doctors and researchers clarified that metformin is not a wonder drug for age-related macular degeneration, but they are confident that it can be prescribed on an even wider basis to help patients who are at risk for losing their vision. It can be the difference between patients progressing from the early stages of macular degeneration to the advanced stages of the condition.
For a patient who is 80 years old and starting to lose their vision due to complications from diabetes, ophthalmologists say that a metformin prescription could “give them another 10 years of vision.”
Regarding the 10-Q
In the filing, it looks like they raised cash through the sales of stock with warrants attached. If you look at who has shares from the company (direct investment or for services rendered), you see Langer BUYING shares--when you see "Subscription Agreement" and "Warrant Exercise", you can se that $600,000 came in from Langer. That is not issuing shares for "services" or "gifting"--real cash. And these shares obtained are RESTRICTED.(SEC Regulations)
If you go to expenses--you see R and D expenses --where some of that cash went. Also, "Professional Services" are probably legal expenses (license agreements, contracts etc.) and accounting services.
Guess some people expect people to work for free--or for building the company to make the shares they paid for when taking over the shell and investing in the Preferred. They cannot sell shares --and their mortgage company an utility company do not accept restricted stock in payment.
In other words, let's get real.
I, too, am disappointed that the IND will not be filed until first quarter next year. And I thought the stock would be higher when the ND ws announced.
But disappointment does not mean I am going negative--because I understand the delays and I see no TOXIC financing in this filing. None of those death spiral converts.
Insiders will only have their liquidity event when the company is SEC reporting and up listed. By buying in the open market, I can have liquidity before the insiders do. (Yes, I paid more than they did, but they took higher risk with an empty shell than I did knowing what they built since--patents. license, NIH vetting, biotech pedigrees in their management team and Scientific Advisory Board.
Good Luck to everyone.
Liquidity for Private Company Securities — Rule 144
For early stage private companies that need to effectively utilize available capital, often times attracting talent comes at the expense of issuing shares of stock (or options to purchase shares of stock) of the company through the use of an equity incentive plan. [v] The issuance of these securities is vital for early stage companies to not only align the interests of employees and other service providers with the interests of investors, but it also allows the company to provide non-cash compensation to its workforce to help reduce the amount of cash outlay that is otherwise needed for purposes of R&D, to help launch a product or to expand the company’s existing presence in the market. But what happens when an employee or other service provider wishes to publicly solicit to sell its shares of stock of the issuing company? Below, I will touch on the general regulatory framework surrounding the offer and sale of securities and then I will discuss the most common securities resale exemption for private company securities in the public marketplace—Rule 144.
The Securities Act of 1933
To understand Rule 144, you should first understand the regulatory framework surrounding Rule 144. The Securities Act of 1933 (the “Securities Act”) governs every offer or sale of securities, whether the issuer of the security is publicly traded or is a privately held company and whether the sale of the issuer’s security is sold by the issuer itself or is a resale of the security by the holder thereof after the initial issuance. The Securities Act requires that any offer or sale of securities be registered with the SEC, unless there exists an exemption from registration. One exemption that many private companies rely upon for issuance of securities under its equity incentive plan is Rule 701 of the Securities Act, which allows an exemption from registration for securities issued by non-reporting companies pursuant to compensatory arrangements. For a resale to the public of these issued securities, however, Rule 701 does not exempt the resale transaction from the registration requirements because the security issued under a company’s equity incentive plan pursuant to Rule 701 is what is referred to as a “restricted security”[ii]. Because most companies issue shares pursuant to an equity incentive plan without granting registration rights to the holders thereof, finding an exemption from registration is the key to allowing a securityholder to publicly solicit the resale of its shares of stock. This is where Rule 144 comes into play.
Rule 144
Rule 144 of the Securities Act is referred to as a “safe harbor” exemption, meaning that as long as the conditions of Rule 144 are met, the individual relying on the transaction exemption in Securities Act Section 4(a)(1) can be assured that they fit within the statutory exemption such that the securityholder will not be deemed an “underwriter” for purposes of Section 4(a)(1).[iii] The below requirements of Rule 144 vary depending on whether the holder of the company’s securities is an “affiliate” of the company, which would include but not be limited to executive officers, directors or significant shareholders in a relationship of control with the issuer.[iv] Sellers who are not affiliates, and who have not been affiliates for the three-month period prior to the sale, must only comply with (1) the holding period requirement and (2) the current public information requirement (which applies, in the case of a non-affiliate holder, only to securities of issuers that are reporting companies). Affiliate sellers of the issuer’s securities must fulfill all five requirements, which are set forth below:
1. Holding Period
The holder of the security must hold the security for a minimum period of time. If the issuer is not a reporting company, then the holding period is a minimum of one year. For the security of an issuer that is subject to the reporting requirements of the Securities Exchange Act of 1934 (the “Exchange Act”), the holder must hold the security for a minimum of six months. Note that in the case of shares held as a result of the exercise of a stock option, the holding period for those shares begins on the date the option was exercised and not on the date the option was granted. Additionally, if a non-affiliate holder purchased the restricted shares from another non-affiliate, then the current holder in most circumstances can “tack” on that non-affiliate’s holding period to satisfy the minimum holding period requirement.
2. Current Public Information
There must be current public information available about the issuer (most of the time). For non-affiliate holders of the securities of an issuer that is not a reporting company, the current public information requirement does not apply, and so long as the shares were held for the minimum holding period noted above, the requirements of Rule 144 have been met. On the other hand, for securities of a non-reporting company held by an affiliate, the public information requirement can be met if certain items of information about the business are publicly disclosed, such as information about the nature of the issuer’s business, its directors and officers and its financial statements.[v] For securities of an issuer that is a reporting company—whether or not the holder of the security is an affiliate—the public information requirement is generally met if the issuer has complied with the periodic reporting requirements of the Exchange Act.
3. Trading Volume Limitation
If the holder of the securities is an affiliate, then the amount of securities that can be sold in any three-month period is limited to the greater of: (1) one percent of the shares of that class outstanding, or (2) if the securities are trading on a stock exchange, the average weekly trading volume of such securities during the four calendar weeks preceding the filing of the Form 144.
4. Manner of Sale
If the holder of the securities is an affiliate, all sales must be “brokers’ transactions” and directly with a “market maker”, or in “riskless principal transactions.” This means that the sales must be handled as routine trading transactions for which the broker receives no more than usual and customary commissions. Additionally, neither the seller nor the broker can solicit orders to buy the securities.
5. Notice of Proposed Sale
If the holder of the securities is an affiliate, the seller must file a notice with the SEC on Form 144 if the sale involves more than 5,000 shares or the aggregate dollar amount is greater than $50,000 in any three-month period.
Conclusion
Rule 144 is a useful tool used by security holders circumvent the public resale restrictions contained in the federal securities laws. Of the five requirements contained in Rule 144, if the holder of the company’s securities is a non-affiliate and the company is a non-reporting company, then only the holding period condition must be met to satisfy Rule 144. Additionally, if the holder is a non-affiliate and the company is reporting company, then only the holding period and current public information conditions of Rule 144 must be met. Otherwise, for affiliate holders, all five conditions must be met in order for the holder to avail itself of the Rule 144 safe harbor. These general requirements of Rule 144 can be nuanced depending on the specific circumstance concerning the proposed resale. It is therefore recommended that you contact knowledgeable counsel to help navigate the regulatory landscape.
See Rule 701 of the Securities Act for the specific requirements of the exemption.
[ii] A “restricted security” is a “security acquired directly or indirectly from the issuer, or from an affiliate of the issuer, in a transaction . . . not involving a public offering.” See Rule 144. Restricted securities are typically received through private placement offerings, equity incentive plans or Regulation D offerings.
[iii] Section 4(a)(1) of the Securities Act exempts a transaction “by a person other than an issuer, underwriter, or dealer.” The Securities Act defines an “underwriter” as “a person who has purchased from an issuer with a view to . . . the distribution of any security. . . .” Rule 144 establishes certain criteria for determining whether a person is not deemed to have engaged in a distribution of a security, and thus would not be an underwriter for purposes of Section 4(a)(1). See Preliminary Note to Rule 144.
[iv] An “Affiliate” is “a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, such issuer.”
[v] For a full list of required public disclosures please see Rule 15c2-11(a)(5)(i) to (xiv) and (xvi).
Private Company Securities in the Public Marketplace - Rule 144 (natlawreview.com)
Kaboom. Almost 7 million shares traded.
Selling bitcoin at these high prices and buying back shares would benefit the shareholders.
Looks like most of that compensation is non cash. Accounting rules that if restricted stock is issued instead of cash, the "compensation" is valued at the market price when issued.
Minimizing cash requirements to advance a business plan is wise.
Would like to see some update on each of their drugs in the pipeline. That page on their website is "Under Construction".
Looks like they filed their 10q early.